Inclusion Criteria:

• - Voluntary and signed informed consent, good compliance.

• - Age: 18 or above (when signing the informed consent form); Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 2; Life expectancy ≥ 24 weeks.

• - Patients diagnosed with Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post PV MF), or post essential thrombocythemia myelofibrosis (post ET MF) - According to the dynamic international prognostic scoring system (DIPSS), patients with intermediate or high risk of bone marrow fibrosis were evaluated.

• - Patients with poor efficacy of JAK inhibitors (for phase Ib and phase II cohort 2) - Patients who had not received JAK inhibitor treatment (for phase II cohort 1).

• - Spleen enlargement.

• - Peripheral blood primary cells and bone marrow primary cells were ≤10%.

• - No growth factor, colony stimulating factor, thrombopoietin or platelet transfusion was received within 2 weeks before the examination, and the blood routine indexes met the requirements within 7 days before the first administration.

• - The Main organ function is normal.

• - Men and women of childbearing age should agree to use contraceptive measures (such as intrauterine devices, contraceptives, or condoms) during the study period and within 6 months after the end of the study.

Serum human chorionic gonadotrophin (HCG) test is not negative within 7 days before the first administration and must be non-lactating patients.

Exclusion Criteria:

• - Patients who have previously received allogeneic stem cell transplantation, or received autologous stem cell transplantation within 3 months before the first administration, or recently planned stem cell transplantation; - Previous treatment with BET inhibitors; - Patients who have previously undergone splenectomy, or received splenic radiotherapy within 6 months before the first administration; - Use of any MF medications, any immunomodulators, androgens, any immunosuppressive agents, erythropoietin, aspirin > 100 mg/day within 2 weeks prior to first administration; - Other malignancies within 3 years prior to first administration or currently present.

• - Patients with multiple factors (such as inability to swallow, postoperative gastrointestinal resection, acute and chronic diarrhea, intestinal obstruction, etc.) affecting oral or absorption of drugs; - Major surgical treatment or significant traumatic injury within 4 weeks prior to first administration; - Presence of congenital bleeding disorder and congenital coagulopathy; - Patients who had arterial/venous thrombosis events within 6 months before the first administration.

• - Have a history of mental drug abuse, or have a mental disorder.

• - Active or uncontrolled severe infection; - Active hepatitis B virus (HBV) infection, or hepatitis C virus (HCV) infection and HCV RNA positive, or active Corona Virus Disease 2019 (COVID-19) infection; - Patients with grade III or above congestive heart failure, unstable angina pectoris or myocardial infarction, or arrhythmia requiring treatment, or QT interval prolongation within 6 months before the first administration; - Unsatisfactory blood pressure control despite standard therapy; - Patients with renal failure requiring hemodialysis or peritoneal dialysis; - Patients newly diagnosed with pulmonary interstitial fibrosis or drug-related interstitial lung disease within 3 months before the first administration; - Patients with a history of immunodeficiency disease or organ transplantation; - Patients with epilepsy requiring treatment; - Patients who have received Chinese patent medicines with anti-tumor indications specified in the approved drug package insert of China National Medical Products Administration (NMPA) within 2 weeks before the first administration; - Patients with uncontrolled pleural effusion, pericardial effusion or ascites; - There was a history of attenuated live vaccine inoculation within 4 weeks before the first administration, or attenuated live vaccine inoculation was planned during the study period.

• - People with known hypersensitivity to the study drug and excipients; - Patients diagnosed as active autoimmune diseases within 2 years before the first administration; - Those who participated in and used other anti-tumor clinical trial drugs within 4 weeks before the first administration (except JAK inhibitor-related clinical trials).

• - According to the judgment of the investigators, some situations seriously endanger the safety of the subjects or affect the subjects to complete the study.

Arms

Experimental: TQ05105 Tablets + TQB3617 Capsules

TQ05105 Tablets combined with TQB3617 Capsules, orally administered. 21 days as a treatment cycle.

Interventions

Drug: - TQ05105 Tablets

TQ05105 Tablets is a Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) Inhibitor.

Drug: - TQB3617 Capsules

TQB3617 Capsules is a Bromodomain and Extra-Terminal (BET) Inhibitor